Barclays analyst Luke Sergott lowered the firm’s price target on Waters (WAT) to $350 from $400 and keeps an Equal Weight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAT:
- Waters upgraded to Overweight from Sector Weight at KeyBanc
- Wingstop initiated, CarMax upgraded: Wall Street’s top analyst calls
- Waters upgraded to Outperform from Neutral at Baird
- Balanced Outlook: Waters Corporation’s Growth Prospects and Risks Underpin Hold Rating
- Balanced Risk-Reward Scenario Justifies Hold Rating for Waters Corporation